House Bill 5882
116th Congress(2019-2020)
GENE Therapy Payment Act
Introduced
Introduced in House on Feb 12, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
5882
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act
This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
February 12, 2020
Sort by most recent
02/12/2020
Referred to the House Committee on Energy and Commerce.
02/12/2020
Introduced in House
Public Record
Record Updated
Feb 8, 2022 11:20:34 PM